| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Stem Neoplasms | 33 | 2023 | 204 | 8.740 |
Why?
|
| Glioma | 38 | 2023 | 3378 | 3.510 |
Why?
|
| Pons | 10 | 2017 | 244 | 2.770 |
Why?
|
| Central Nervous System Neoplasms | 9 | 2022 | 894 | 2.160 |
Why?
|
| Endpoint Determination | 3 | 2020 | 598 | 1.780 |
Why?
|
| Macaca mulatta | 16 | 2020 | 2380 | 1.750 |
Why?
|
| Brain Neoplasms | 25 | 2022 | 8788 | 1.440 |
Why?
|
| Antineoplastic Agents | 17 | 2023 | 13622 | 1.220 |
Why?
|
| Medulloblastoma | 5 | 2022 | 677 | 1.130 |
Why?
|
| Cerebrospinal Fluid | 2 | 2020 | 536 | 1.010 |
Why?
|
| Blood-Brain Barrier | 6 | 2020 | 1013 | 1.000 |
Why?
|
| Dacarbazine | 6 | 2017 | 567 | 0.980 |
Why?
|
| Astrocytoma | 3 | 2023 | 789 | 0.930 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2023 | 51 | 0.900 |
Why?
|
| Magnetic Resonance Spectroscopy | 6 | 2018 | 3752 | 0.810 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2020 | 2037 | 0.800 |
Why?
|
| Thalidomide | 2 | 2020 | 878 | 0.790 |
Why?
|
| Models, Animal | 4 | 2016 | 2166 | 0.760 |
Why?
|
| Inulin | 1 | 2020 | 84 | 0.760 |
Why?
|
| Cerebellar Neoplasms | 4 | 2022 | 582 | 0.740 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2020 | 87 | 0.730 |
Why?
|
| Child | 65 | 2023 | 77029 | 0.720 |
Why?
|
| Neutropenia | 2 | 2023 | 888 | 0.680 |
Why?
|
| Public Health Practice | 2 | 2018 | 217 | 0.650 |
Why?
|
| Baltimore | 6 | 2018 | 230 | 0.650 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2018 | 315 | 0.640 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 45 | 0.640 |
Why?
|
| Phosphorylcholine | 2 | 2017 | 162 | 0.640 |
Why?
|
| Magnetic Resonance Imaging | 25 | 2023 | 35274 | 0.620 |
Why?
|
| Designer Drugs | 1 | 2017 | 20 | 0.600 |
Why?
|
| Child, Preschool | 41 | 2020 | 40801 | 0.590 |
Why?
|
| Bradykinin | 5 | 2006 | 214 | 0.580 |
Why?
|
| Interinstitutional Relations | 1 | 2018 | 241 | 0.580 |
Why?
|
| Thrombocytopenia | 2 | 2023 | 1170 | 0.560 |
Why?
|
| Aminopyridines | 1 | 2020 | 539 | 0.560 |
Why?
|
| Carboplatin | 6 | 2011 | 799 | 0.530 |
Why?
|
| Measles | 1 | 2017 | 170 | 0.530 |
Why?
|
| Pyrroles | 3 | 2022 | 1142 | 0.520 |
Why?
|
| Choline | 3 | 2012 | 487 | 0.510 |
Why?
|
| Cannabinoids | 1 | 2017 | 167 | 0.500 |
Why?
|
| Aspartic Acid | 3 | 2012 | 575 | 0.490 |
Why?
|
| Alcoholic Beverages | 1 | 2016 | 264 | 0.480 |
Why?
|
| Catheters, Indwelling | 2 | 2016 | 422 | 0.470 |
Why?
|
| Tumor Burden | 5 | 2022 | 1904 | 0.470 |
Why?
|
| Neoplasms, Nerve Tissue | 1 | 2013 | 23 | 0.460 |
Why?
|
| Microdialysis | 1 | 2013 | 158 | 0.460 |
Why?
|
| Alcohol-Related Disorders | 1 | 2016 | 234 | 0.460 |
Why?
|
| Guanine | 3 | 2011 | 271 | 0.450 |
Why?
|
| Catheterization | 2 | 2016 | 1466 | 0.440 |
Why?
|
| Brain Stem | 4 | 2017 | 849 | 0.420 |
Why?
|
| Adolescent | 41 | 2022 | 85409 | 0.410 |
Why?
|
| Meningeal Neoplasms | 2 | 2018 | 1234 | 0.410 |
Why?
|
| Pharmaceutical Preparations | 1 | 2019 | 1066 | 0.390 |
Why?
|
| Area Under Curve | 7 | 2018 | 1653 | 0.380 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2011 | 496 | 0.360 |
Why?
|
| Specimen Handling | 1 | 2015 | 692 | 0.360 |
Why?
|
| Bayes Theorem | 1 | 2018 | 2299 | 0.360 |
Why?
|
| Hydroxamic Acids | 2 | 2015 | 495 | 0.350 |
Why?
|
| Protons | 3 | 2011 | 1120 | 0.350 |
Why?
|
| Maximum Tolerated Dose | 5 | 2020 | 888 | 0.350 |
Why?
|
| Ethanol | 1 | 2016 | 1329 | 0.340 |
Why?
|
| Age of Onset | 3 | 2020 | 3263 | 0.340 |
Why?
|
| Standard of Care | 1 | 2013 | 563 | 0.340 |
Why?
|
| Male | 56 | 2023 | 348967 | 0.330 |
Why?
|
| Humans | 93 | 2023 | 739219 | 0.330 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2009 | 140 | 0.320 |
Why?
|
| Ependymoma | 3 | 2022 | 333 | 0.320 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 2731 | 0.320 |
Why?
|
| Supratentorial Neoplasms | 1 | 2009 | 160 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2020 | 10939 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2023 | 11411 | 0.300 |
Why?
|
| Interferon-alpha | 1 | 2011 | 895 | 0.300 |
Why?
|
| Consensus | 4 | 2020 | 2912 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 2507 | 0.300 |
Why?
|
| Administration, Intranasal | 2 | 2018 | 445 | 0.280 |
Why?
|
| Tissue Distribution | 3 | 2020 | 2335 | 0.280 |
Why?
|
| Metabolic Clearance Rate | 3 | 2018 | 379 | 0.270 |
Why?
|
| Public Health | 2 | 2016 | 2587 | 0.270 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 1180 | 0.270 |
Why?
|
| Molecular Imaging | 1 | 2012 | 821 | 0.260 |
Why?
|
| Chromosome Aberrations | 1 | 2011 | 1811 | 0.250 |
Why?
|
| Health Promotion | 1 | 2017 | 2187 | 0.250 |
Why?
|
| Infusions, Intravenous | 7 | 2015 | 2270 | 0.250 |
Why?
|
| Animals | 27 | 2023 | 168358 | 0.250 |
Why?
|
| Positron-Emission Tomography | 5 | 2022 | 6247 | 0.250 |
Why?
|
| Neoplasms | 8 | 2019 | 21499 | 0.240 |
Why?
|
| Half-Life | 4 | 2018 | 658 | 0.240 |
Why?
|
| Time Factors | 10 | 2020 | 40040 | 0.240 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2008 | 290 | 0.240 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2014 | 2299 | 0.230 |
Why?
|
| Radiation Tolerance | 2 | 2017 | 485 | 0.230 |
Why?
|
| Osteosarcoma | 1 | 2009 | 884 | 0.230 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 2057 | 0.230 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 15035 | 0.230 |
Why?
|
| Doxorubicin | 2 | 2000 | 2215 | 0.230 |
Why?
|
| Infant | 17 | 2018 | 34923 | 0.220 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2022 | 2009 | 0.220 |
Why?
|
| Drug Administration Schedule | 6 | 2013 | 4935 | 0.210 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2007 | 788 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 5500 | 0.210 |
Why?
|
| Research Design | 1 | 2018 | 5959 | 0.210 |
Why?
|
| Organoplatinum Compounds | 2 | 2015 | 407 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 1045 | 0.200 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2022 | 1239 | 0.200 |
Why?
|
| Gangliosides | 1 | 2022 | 140 | 0.200 |
Why?
|
| Exotoxins | 2 | 2018 | 119 | 0.190 |
Why?
|
| Female | 39 | 2020 | 378808 | 0.190 |
Why?
|
| Intracranial Pressure | 1 | 2023 | 327 | 0.190 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 4239 | 0.190 |
Why?
|
| Stroke | 1 | 2023 | 9898 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 7897 | 0.180 |
Why?
|
| Young Adult | 17 | 2022 | 56252 | 0.180 |
Why?
|
| Prognosis | 9 | 2022 | 28901 | 0.180 |
Why?
|
| Brain | 5 | 2023 | 26293 | 0.180 |
Why?
|
| Nasal Mucosa | 1 | 2023 | 372 | 0.180 |
Why?
|
| Craniopharyngioma | 1 | 2023 | 281 | 0.180 |
Why?
|
| Rhabdoid Tumor | 1 | 2022 | 211 | 0.180 |
Why?
|
| Fluconazole | 1 | 2000 | 145 | 0.180 |
Why?
|
| Biological Availability | 1 | 2020 | 390 | 0.170 |
Why?
|
| Interleukin-13 | 2 | 2018 | 388 | 0.170 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2017 | 358 | 0.170 |
Why?
|
| Histones | 2 | 2022 | 2592 | 0.170 |
Why?
|
| Infusions, Intraventricular | 1 | 2018 | 36 | 0.170 |
Why?
|
| Perfusion Imaging | 1 | 2020 | 194 | 0.160 |
Why?
|
| Sickle Cell Trait | 1 | 1999 | 81 | 0.160 |
Why?
|
| Carcinoma, Medullary | 1 | 1999 | 122 | 0.160 |
Why?
|
| Creatine | 2 | 2012 | 421 | 0.160 |
Why?
|
| Smith-Lemli-Opitz Syndrome | 1 | 2017 | 46 | 0.160 |
Why?
|
| Local Government | 1 | 2018 | 79 | 0.160 |
Why?
|
| Neoplasm Seeding | 1 | 2018 | 87 | 0.150 |
Why?
|
| Drug Labeling | 1 | 2019 | 230 | 0.150 |
Why?
|
| Hematuria | 1 | 1999 | 234 | 0.150 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 480 | 0.150 |
Why?
|
| Organizational Case Studies | 1 | 2018 | 299 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 1833 | 0.150 |
Why?
|
| Neurofibromatosis 1 | 2 | 2017 | 558 | 0.150 |
Why?
|
| Measles Vaccine | 1 | 2017 | 76 | 0.150 |
Why?
|
| Administration, Oral | 3 | 2015 | 3909 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 2521 | 0.150 |
Why?
|
| Cyclosporine | 1 | 2000 | 782 | 0.150 |
Why?
|
| Cerebral Cortex | 1 | 2013 | 5717 | 0.150 |
Why?
|
| Registries | 5 | 2022 | 8039 | 0.150 |
Why?
|
| Immunomodulation | 1 | 2020 | 540 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 3800 | 0.140 |
Why?
|
| Survival Rate | 5 | 2017 | 12760 | 0.140 |
Why?
|
| Treatment Outcome | 10 | 2023 | 62691 | 0.140 |
Why?
|
| Benzoxazoles | 1 | 2017 | 81 | 0.140 |
Why?
|
| Civil Disorders | 1 | 2015 | 8 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 6517 | 0.140 |
Why?
|
| Powders | 1 | 2016 | 80 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2000 | 688 | 0.140 |
Why?
|
| Public Health Administration | 1 | 2018 | 241 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2022 | 908 | 0.130 |
Why?
|
| Antifungal Agents | 1 | 2000 | 722 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2019 | 1374 | 0.130 |
Why?
|
| Social Problems | 1 | 2015 | 112 | 0.130 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 325 | 0.120 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 779 | 0.120 |
Why?
|
| Pituitary Neoplasms | 1 | 2023 | 1334 | 0.120 |
Why?
|
| Valproic Acid | 1 | 2017 | 444 | 0.120 |
Why?
|
| Autopsy | 2 | 2016 | 1003 | 0.120 |
Why?
|
| Civil Defense | 1 | 2015 | 110 | 0.120 |
Why?
|
| Pyrimidines | 2 | 2017 | 2917 | 0.120 |
Why?
|
| Injections, Intravenous | 3 | 2013 | 1420 | 0.120 |
Why?
|
| Lateral Ventricles | 1 | 2015 | 141 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2020 | 961 | 0.120 |
Why?
|
| 5-Methylcytosine | 1 | 2014 | 153 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 953 | 0.120 |
Why?
|
| Police | 1 | 2015 | 145 | 0.120 |
Why?
|
| Brain Edema | 1 | 2018 | 617 | 0.120 |
Why?
|
| Vincristine | 1 | 2015 | 1038 | 0.120 |
Why?
|
| SEER Program | 1 | 2018 | 1506 | 0.110 |
Why?
|
| Cytosine | 1 | 2014 | 212 | 0.110 |
Why?
|
| State Government | 1 | 2016 | 371 | 0.110 |
Why?
|
| Benzazepines | 1 | 2015 | 326 | 0.110 |
Why?
|
| Poultry Diseases | 1 | 2012 | 25 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2018 | 3769 | 0.110 |
Why?
|
| DNA, Neoplasm | 2 | 2022 | 1755 | 0.100 |
Why?
|
| Adult | 20 | 2022 | 213375 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2022 | 2100 | 0.100 |
Why?
|
| Salmonella Infections, Animal | 1 | 2012 | 65 | 0.100 |
Why?
|
| Fourth Ventricle | 1 | 2012 | 30 | 0.100 |
Why?
|
| Community Health Services | 1 | 2017 | 652 | 0.100 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 1584 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 623 | 0.100 |
Why?
|
| Prospective Studies | 7 | 2022 | 53036 | 0.100 |
Why?
|
| Indoles | 2 | 2022 | 1833 | 0.100 |
Why?
|
| Attitude to Death | 1 | 2014 | 381 | 0.100 |
Why?
|
| Cholesterol | 2 | 2017 | 2897 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2017 | 1453 | 0.100 |
Why?
|
| Drug Carriers | 1 | 2015 | 691 | 0.100 |
Why?
|
| Basilar Artery | 1 | 2012 | 200 | 0.100 |
Why?
|
| Zoonoses | 1 | 2012 | 184 | 0.100 |
Why?
|
| DNA Modification Methylases | 1 | 2011 | 205 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2016 | 8395 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 2454 | 0.090 |
Why?
|
| Health Education | 1 | 2017 | 1054 | 0.090 |
Why?
|
| Paraffin Embedding | 1 | 2011 | 299 | 0.090 |
Why?
|
| Salmonella Infections | 1 | 2012 | 174 | 0.090 |
Why?
|
| Bereavement | 1 | 2014 | 273 | 0.090 |
Why?
|
| Camptothecin | 1 | 2013 | 569 | 0.090 |
Why?
|
| Disease Outbreaks | 2 | 2017 | 1779 | 0.090 |
Why?
|
| International Cooperation | 1 | 2017 | 1420 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 1637 | 0.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 627 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2019 | 8272 | 0.090 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 2881 | 0.090 |
Why?
|
| Organs at Risk | 1 | 2012 | 347 | 0.090 |
Why?
|
| DNA Repair Enzymes | 1 | 2011 | 347 | 0.090 |
Why?
|
| Neurology | 1 | 2018 | 762 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 641 | 0.090 |
Why?
|
| Infant, Newborn | 7 | 2022 | 25470 | 0.090 |
Why?
|
| Disaster Planning | 1 | 2015 | 550 | 0.090 |
Why?
|
| United States | 7 | 2019 | 69568 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 13880 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2014 | 848 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 3557 | 0.080 |
Why?
|
| Epigenomics | 1 | 2014 | 891 | 0.080 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 2370 | 0.080 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 1095 | 0.080 |
Why?
|
| Radiopharmaceuticals | 2 | 2022 | 2649 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2001 | 4025 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 12328 | 0.080 |
Why?
|
| Informed Consent | 1 | 2014 | 988 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 38941 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 6478 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 6870 | 0.070 |
Why?
|
| Gaucher Disease | 1 | 2007 | 114 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2017 | 2629 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2013 | 9124 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2016 | 1843 | 0.070 |
Why?
|
| Mutation | 3 | 2022 | 29659 | 0.070 |
Why?
|
| Maternal Behavior | 1 | 2008 | 311 | 0.070 |
Why?
|
| Health Policy | 1 | 2018 | 2655 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2727 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2008 | 618 | 0.070 |
Why?
|
| Combined Modality Therapy | 4 | 2011 | 8605 | 0.070 |
Why?
|
| Hydrocephalus | 1 | 2012 | 744 | 0.070 |
Why?
|
| Age Factors | 5 | 2018 | 18347 | 0.060 |
Why?
|
| Hematologic Diseases | 1 | 2009 | 498 | 0.060 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 3629 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2023 | 21859 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2018 | 6218 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 11348 | 0.060 |
Why?
|
| Mother-Child Relations | 1 | 2008 | 479 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2012 | 5050 | 0.060 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2004 | 69 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 18002 | 0.060 |
Why?
|
| Quality of Life | 4 | 2023 | 12640 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2019 | 1790 | 0.060 |
Why?
|
| Biopsy | 2 | 2013 | 6722 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2018 | 5108 | 0.060 |
Why?
|
| Disease Progression | 3 | 2018 | 13237 | 0.060 |
Why?
|
| Perfusion | 1 | 2007 | 1353 | 0.050 |
Why?
|
| Contrast Media | 2 | 2014 | 5287 | 0.050 |
Why?
|
| Mice | 4 | 2023 | 80995 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 1999 | 4190 | 0.050 |
Why?
|
| Observer Variation | 1 | 2008 | 2587 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2014 | 551 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 2215 | 0.050 |
Why?
|
| Man-Machine Systems | 1 | 2001 | 44 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 6609 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2022 | 8919 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2018 | 4537 | 0.050 |
Why?
|
| Flushing | 1 | 2001 | 49 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2009 | 1578 | 0.050 |
Why?
|
| Pyrimidine Nucleosides | 1 | 2000 | 7 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 2843 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 5128 | 0.050 |
Why?
|
| Drug Interactions | 2 | 2009 | 1456 | 0.050 |
Why?
|
| Schizophrenic Psychology | 1 | 2008 | 1677 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2011 | 2564 | 0.050 |
Why?
|
| Parents | 1 | 2014 | 3368 | 0.050 |
Why?
|
| Family | 1 | 2011 | 3141 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2012 | 2627 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 7274 | 0.050 |
Why?
|
| Caregivers | 1 | 2011 | 2067 | 0.040 |
Why?
|
| Infusions, Intralesional | 1 | 2018 | 3 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 1998 | 0.040 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2022 | 282 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 3328 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2007 | 1005 | 0.040 |
Why?
|
| Algorithms | 2 | 2018 | 13828 | 0.040 |
Why?
|
| Alkaloids | 1 | 2000 | 189 | 0.040 |
Why?
|
| Recurrence | 1 | 2010 | 8306 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 19787 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 7626 | 0.040 |
Why?
|
| Pseudomonas | 1 | 2018 | 117 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2018 | 232 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2007 | 1934 | 0.040 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2000 | 690 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 16624 | 0.040 |
Why?
|
| Gadolinium DTPA | 2 | 2014 | 836 | 0.040 |
Why?
|
| Choroid Plexus | 1 | 2000 | 230 | 0.040 |
Why?
|
| Lactones | 1 | 2019 | 329 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 603 | 0.040 |
Why?
|
| Seizures | 2 | 2017 | 2829 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2018 | 181 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 205 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 9812 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2018 | 23292 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 14721 | 0.040 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2017 | 199 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2004 | 2184 | 0.030 |
Why?
|
| New Zealand | 1 | 2017 | 355 | 0.030 |
Why?
|
| Amino Acids | 1 | 2022 | 1727 | 0.030 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2016 | 75 | 0.030 |
Why?
|
| Activin Receptors, Type I | 1 | 2016 | 143 | 0.030 |
Why?
|
| Sphingomyelins | 1 | 2015 | 105 | 0.030 |
Why?
|
| Hypotension | 1 | 2001 | 881 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2013 | 76632 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2000 | 1223 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 10961 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2008 | 6963 | 0.030 |
Why?
|
| Basal Ganglia | 1 | 2017 | 547 | 0.030 |
Why?
|
| Cerebrum | 1 | 2016 | 137 | 0.030 |
Why?
|
| Convection | 1 | 2014 | 31 | 0.030 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2016 | 336 | 0.030 |
Why?
|
| Cell Death | 1 | 2019 | 1691 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1999 | 1850 | 0.030 |
Why?
|
| Stereotaxic Techniques | 1 | 2016 | 535 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2000 | 1127 | 0.030 |
Why?
|
| Headache | 1 | 2001 | 1199 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 603 | 0.030 |
Why?
|
| Australia | 1 | 2017 | 1162 | 0.030 |
Why?
|
| Mitotic Index | 1 | 2013 | 171 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 2000 | 930 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 1866 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2014 | 440 | 0.030 |
Why?
|
| Liposomes | 1 | 2015 | 759 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 961 | 0.030 |
Why?
|
| Poultry | 1 | 2012 | 82 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2017 | 2714 | 0.030 |
Why?
|
| Salmonella | 1 | 2012 | 128 | 0.030 |
Why?
|
| Serotyping | 1 | 2012 | 339 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 2021 | 0.030 |
Why?
|
| Metabolomics | 1 | 2019 | 1460 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 749 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 2503 | 0.020 |
Why?
|
| Death | 1 | 2015 | 670 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2017 | 1119 | 0.020 |
Why?
|
| Catheters | 1 | 2014 | 419 | 0.020 |
Why?
|
| Proteinuria | 1 | 2013 | 654 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2008 | 2870 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2008 | 5148 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 2028 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2017 | 1362 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2017 | 23355 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3599 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 71972 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2015 | 3688 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2000 | 3670 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 5180 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2000 | 4454 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 1821 | 0.020 |
Why?
|
| Software | 1 | 2001 | 4425 | 0.020 |
Why?
|
| Infant Behavior | 1 | 2008 | 156 | 0.020 |
Why?
|
| Infant Care | 1 | 2008 | 184 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 2933 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 1524 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 2448 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2017 | 8414 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2022 | 9393 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 9738 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 2944 | 0.020 |
Why?
|
| Equipment Design | 1 | 2014 | 3576 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 7716 | 0.020 |
Why?
|
| DNA Repair | 1 | 2015 | 2032 | 0.020 |
Why?
|
| Cisplatin | 1 | 2011 | 1615 | 0.020 |
Why?
|
| HIV Infections | 1 | 2011 | 16763 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3510 | 0.020 |
Why?
|
| Cell Movement | 1 | 2017 | 5220 | 0.020 |
Why?
|
| Facial Paralysis | 1 | 2007 | 300 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 2007 | 766 | 0.010 |
Why?
|
| Kidney | 1 | 1999 | 7141 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2006 | 40385 | 0.010 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 1153 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2000 | 9259 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2011 | 6364 | 0.010 |
Why?
|
| Automation | 1 | 2004 | 582 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 24711 | 0.010 |
Why?
|
| Social Support | 1 | 2011 | 2112 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2013 | 3440 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10446 | 0.010 |
Why?
|
| Apoptosis | 1 | 2017 | 9708 | 0.010 |
Why?
|
| Idoxuridine | 1 | 2000 | 123 | 0.010 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2000 | 87 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2016 | 6661 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 5833 | 0.010 |
Why?
|
| Incidence | 1 | 2018 | 20912 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2014 | 4268 | 0.010 |
Why?
|
| Ferrets | 1 | 2000 | 194 | 0.010 |
Why?
|
| Hematologic Tests | 1 | 2000 | 237 | 0.010 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 1628 | 0.010 |
Why?
|
| Staurosporine | 1 | 2000 | 251 | 0.010 |
Why?
|
| Patient Participation | 1 | 2008 | 1441 | 0.010 |
Why?
|
| Urine | 1 | 2000 | 370 | 0.010 |
Why?
|
| Prodrugs | 1 | 2000 | 268 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2005 | 1524 | 0.010 |
Why?
|
| Neurons | 1 | 2017 | 9340 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2007 | 2755 | 0.010 |
Why?
|
| Neurosurgical Procedures | 1 | 2007 | 1994 | 0.010 |
Why?
|
| Stomach | 1 | 2000 | 696 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1999 | 20038 | 0.010 |
Why?
|
| Sex Factors | 1 | 2009 | 10397 | 0.010 |
Why?
|
| Hypertension | 1 | 2013 | 8430 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2000 | 2933 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2008 | 6867 | 0.010 |
Why?
|
| Middle Aged | 2 | 2014 | 212833 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2000 | 3453 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 57639 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 2000 | 4662 | 0.000 |
Why?
|
| DNA | 1 | 2000 | 7278 | 0.000 |
Why?
|
| Liver | 1 | 2000 | 7446 | 0.000 |
Why?
|
| Aged | 2 | 2012 | 162667 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 2000 | 10140 | 0.000 |
Why?
|